Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 101–200 of 943
Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease
Sepers, M. D., & Raymond, L. A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.006 · Cited by 149
Characterization of the SARS‐CoV ‐2 E Protein: Sequence, Structure, Viroporin, and Inhibitors
Cao, Y., Yang, R., Lee, I., Zhang, W., Sun, J., Wang, W., & Meng, X. (2021) · Protein Science · doi:10.1002/pro.4075 · Cited by 150
“It is also inhibits the NMDA receptor, similar to the inhibitory effect of AMT on the virus.(129) Memantine has anti-inflammatory effects.”
Sánchez‐Blázquez, P., Rodríguez-Muñoz, M., & Garzón, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00169 · Cited by 141
“…of NMDARs by cannabinoids is particularly relevant because their persistent activation produces a series of perturbations that may lead to neurodegenerative diseases (Lipton, 2006), mood disorders, such as depression (Maeng and Zarate, 2007), and neuropathic pain (Sigtermans et al., 2009).”
BackgroundKranaster, L., Kammerer-Ciernioch, J., Hoyer, C., & Sartorius, A. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0205-7 · Cited by 144
“Other clinically used NMDA antagonists such as memantine have extensively been demonstrated to act protectively in the treatment of dementia [34].”
Neurotransmitters Drive Combinatorial Multistate Postsynaptic Density Networks
Coba, M. P., Pocklington, A. J., Collins, M. O., Kopanitsa, M. V., Uren, R. T., Swamy, S., Croning, M. D. R., Choudhary, J. S., & Grant, S. G. N. (2009) · Science Signaling · doi:10.1126/scisignal.2000102 · Cited by 129
Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
Farlow, M. R., Miller, M. L., & Pejovic, V. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122962 · Cited by 129
“Preclinical studies with memantine are consistent with a putative neuroprotective role [”
ResultClinical practice: The management of hyperammonemia
Häberle, J. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-010-1369-2 · Cited by 131
Haun, F., Nakamura, T., Shiu, A. D., Cho, D.-H., Tsunemi, T., Holland, E. A., La Spada, A. R., & Lipton, S. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4928 · Cited by 125
“This finding is emblematic of an emerging theme in both genetic and sporadic neurodegenerative disorders that nitrosative stress caused by excessive generation of NO can contribute to neuronal cell injury and death (28, 37, 39).”
Self-citationMechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities
Macrez, R., Stys, P. K., Vivien, D., Lipton, S. A., & Docagne, F. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30165-x · Cited by 127
Self-citationAn Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration
Boxer, A. L., Lipton, A. M., Womack, K., Merrilees, J., Neuhaus, J., Pavlic, D., Gandhi, A., Red, D., Martin-Cook, K., Svetlik, D., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318197852f · Cited by 122
“The secondary objectives of the study were to explore whether memantine treatment was associated with a stabilization or improvement in the neuropsychiatric, cognitive, motor, or functional impairments associated with FTLD. Secondary outcome measures are listed in detail below.”
BackgroundInfluentialVizi, E. S., Kisfali, M., & Lőrincz, T. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.10.005 · Cited by 133
Mechanism of acute tryptophan depletion: is it only serotonin?
van Donkelaar, E. L., Blokland, A., Ferrington, L., Kelly, P. A. T., Steinbusch, H. W. M., & Prickaerts, J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.9 · Cited by 140
“151 but antagonists can also have a neuroprotective effect”
BackgroundTherapeutic Strategies for Alzheimer’s Disease
Barten, D. M., & Albright, C. F. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8031-2 · Cited by 132
“without influencing normal receptor function [169].”
Involvement of in the abnormal hyperphosphorylation of tau and its reversal by Memantine
Chohan, M. O., Khatoon, S., Iqbal, I.-G., & Iqbal, K. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.06.021 · Cited by 119
“It is this excessive opening of the NMDAR channels which allows Memantine to gain access to the internal Mg2+ binding site.”
BackgroundResultInfluentialTang, Z., Arjunan, P., Lee, C., Li, Y., Kumar, A., Hou, X., Wang, B., Wardęga, P., Zhang, F., Dong, L., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091704 · Cited by 123
“With the promise offered by the studies on Alzheimer’s disease (Reisberg et al., 2003; Lipton, 2006) and amyotrophic lateral sclerosis (Nirmalananthan and Greensmith, 2005), neuroprotection achieved by neuroprotective factors to enhance neuronal survival has emerged to be a potentially promising…”
BackgroundNyakas, C. J., Granic, I., Halmy, L. G., Banerjee, P., & Luiten, P. G. M. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.033 · Cited by 138
“Note that in the Alzheimer’ marked by white arrows), which might be considered as aberrant en passant syna he control and Alzheimer’s cases, although much less are present in latter case.”
BackgroundFrom Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
Zheng, H., Fridkin, M., & Youdim, M. (2014) · Pharmaceuticals · doi:10.3390/ph7020113 · Cited by 120
“Moreover, these types of antagonists work better to block normal function than pathological activity, and thus lead to clinically unaccepted side effects [18,22].”
BackgroundInfluentialRecent insights into the mode of action of memantine and ketamine
Johnson, J. W., Glasgow, N. G., & Povysheva, N. V. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.006 · Cited by 116
Liu, D., Pitta, M., Lee, J.-H., Ray, B., Lahiri, D. K., Furukawa, K., Mughal, M., Jiang, H., Villarreal, J., Cutler, R. G., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101017 · Cited by 114
“The role of NMDA receptor overactivation in excitotoxic damage to neurons led to the development the NMDA receptor channel blocker memantine as a therapeutic that can slow cognitive decline in some patients with moderate to severe AD [8].”
Lockrow, J., Boger, H., Bimonte-Nelson, H., & Granholm, A.-C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.03.036 · Cited by 116
“NMDA receptors, due to their high permeability to Ca2+ and their slow-gating kinetics, are also implicated in excitotoxic neuronal damage that has been implicated in several neurodegenerative disorders, including AD [50].”
BackgroundNeuroprotection by the NR3A Subunit of the NMDA Receptor
Nakanishi, N., Tu, S., Shin, Y., Cui, J., Kurokawa, T., Zhang, D., Chen, H.-S. V., Tong, G., & Lipton, S. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1067-09.2009 · Cited by 117
“…shown that the inhibitory mechanism of action of memantine involves open-channel block of the NMDAR channels, and in a somewhat similar manner the inhibitory action of NR3A involves blocking of the outer vestibule of the channel (Chen et al., 1992; Chen and Lipton, 2005; Lipton, 2006, 2007).”
BackgroundSelf-citationStys, P. K., You, H., & Zamponi, G. W. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.225276 · Cited by 115
“memantine, which is an NMDA receptor antagonist with relatively modest side effects (Lipton, 2006; Olivares et al. 2011).”
BackgroundInfluentialImaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo
Cordeiro, M. F., Guo, L., Coxon, K. M., Duggan, J., Nizari, S., Normando, E. M., Sensi, S. L., Sillito, A. M., Fitzke, F. W., Salt, T. E., et al. (2010) · Cell Death & Disease · doi:10.1038/cddis.2009.3 · Cited by 113
Nakamura, T., Cho, D., & Lipton, S. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.032 · Cited by 124
“Neuronal damage caused by excessive activation of glutamate receptors is known as “Excitotoxicity” (Olney, 1969), and excessive Ca influx through NMDA receptor-associated ion channels is at least partially responsible for this form of neurotoxicity (Chen and Lipton, 2006; Lipton, 2006; Lipton and Rosenberg, 1994).”
InfluentialSelf-citationSerine Racemase Deletion Protects Against Cerebral Ischemia and Excitotoxicity
Mustafa, A. K., Ahmad, A. S., Zeynalov, E., Gazi, S. K., Sikka, G., Ehmsen, J. T., Barrow, R. K., Coyle, J. T., Snyder, S. H., & Doré, S. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4297-09.2010 · Cited by 114
“The marked reduction in infarct volume of SR / animals following MCAO is comparable to protection against stroke damage associated with pharmacologic blockade of NMDA receptors (Lipton, 2006).”
Zhang, G., Dong, Y., Zhang, B., Ichinose, F., Wu, X., Culley, D. J., Crosby, G. J., Tanzi, R. E., & Xie, Z. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5694-07.2008 · Cited by 121
ADDLs and the signaling web that leads to Alzheimer’s disease
Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 122
“been approved for treatment of moderate to severe AD (Chen and Lipton, 2006; Doody et al., 2004; Lipton, 2006).”
BackgroundHall, D. A., Birch, R. C., Anheim, M., Jønch, A. E., Pintado, E., O’Keefe, J., Trollor, J. N., Stebbins, G. T., Hagerman, R. J., Fahn, S., et al. (2014) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-6-31 · Cited by 112
“Memantine for FXTAS Memantine, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptor approved for the treatment of moderate to severe AD, has been suggested to be of therapeutic benefit in a number of neurological disorders associated with over-activation of glutamate receptors, including AD, PD, and Hunting…”
BackgroundAβ Oligomers Induce Glutamate Release from Hippocampal Neurons
Brito-Moreira, J., C. Paula-Lima, A., R. Bomfim, T., F. Oliveira, F., J. Sepulveda, F., G. De Mello, F., G. Aguayo, L., Panizzutti, R., & T. Ferreira, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391917 · Cited by 96
“Dysregulation of glutamate signaling is thought to play an important role in A -induced neurotoxicity in AD (for reviews, see [17,18,49]).”
BackgroundExpanding Role of NMDA Receptor Antagonists in the Management of Pain
Kreutzwiser, D., & Tawfic, Q. A. (2019) · CNS Drugs · doi:10.1007/s40263-019-00618-2 · Cited by 106
Modeling Intracerebal Hemorrhage: Glutamate, Nuclear Factor-κB Signaling and Cytokines
Wagner, K. R. (2007) · Stroke · doi:10.1161/01.str.0000255033.02904.db · Cited by 108
Schallier, A., Smolders, I., Van Dam, D., Loyens, E., De Deyn, P. P., Michotte, A., Michotte, Y., & Massie, A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101005 · Cited by 109
“Excitotoxic injury occurs in part because of overactivation of N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors, permitting excessive Ca2+ influx through receptor associated ion channels [2].”
Nakamura, T., & Lipton, S. A. (2010) · Apoptosis · doi:10.1007/s10495-010-0476-x · Cited by 107
“While many intra- and extracellular molecules may participate in neuronal injury, accumulation of nitrosative stress due to excessive generation of nitric oxide (NO) appears to be a potential factor contributing to neuronal cell damage and death [6, 7].”
BackgroundSelf-citationEmerging Roles of S -Nitrosylation in Protein Misfolding and Neurodegenerative Diseases
Nakamura, T., & Lipton, S. A. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1858 · Cited by 107
“While many intra-and extracellular molecules may participate in neuronal injury, accumulation of nitrosative stress due to excessive generation of nitric oxide (NO) appears to be a potential factor contributing to neuronal cell damage and death (86, 90).”
InfluentialSelf-citationSlow Excitotoxicity in Alzheimer's Disease
Ong, W.-Y., Tanaka, K., Dawe, G. S., Ittner, L. M., & Farooqui, A. A. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121990 · Cited by 100
“The NitroMemantines have enhanced neuroprotective efficacy in vitro, and in animal models of neurological disorders [261, 262].”
Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization
Glasgow, N. G., Povysheva, N. V., Azofeifa, A. M., & Johnson, J. W. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1173-17.2017 · Cited by 98
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial
Lovera, J., Frohman, E., Brown, T., Bandari, D., Nguyen, L., Yadav, V., Stuve, O., Karman, J., Bogardus, K., Heimburger, G., et al. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510367662 · Cited by 105
“In theory memantine allows neurons to continue to transmit signals while it reduces the noise created by abnormally high levels of extracellular glutamate.(24) Glutamate transport is altered in patients with MS(25,26) and the levels of glutamate, measured by MR spectroscopy, are known to be elevated in the normal whit…”
BackgroundNeurotransmitter changes after traumatic brain injury: an update for new treatment strategies
McGuire, J. L., Ngwenya, L. B., & McCullumsmith, R. E. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0239-6 · Cited by 112
Memantine induces reversible neurologic impairment in patients with MS
Villoslada, P., Arrondo, G., Sepulcre, J., Alegre, M., & Artieda, J. (2009) · Neurology · doi:10.1212/01.wnl.0000342388.73185.80 · Cited by 105
Nakamura, T., & Lipton, S. A. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3570 · Cited by 104
“…sites, whereas NR2B is enriched at extra-synaptic sites but this differential localization is not exclusive; the subcellular localization of NR2 subtypes at best can only explain in part the differential effects of synaptic and extra-synaptic NMDA receptor activity on neuronal survival (79).”
InfluentialSelf-citationGubandru, M., Margina, D. M., Tsitsimpikou, C., Goutzourelas, N., Tsarouhas, K., Ilie, M., Tsatsakis, A. M., & Kouretas, D. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.013 · Cited by 107
Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats
Kumar, H., & Sharma, B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.013 · Cited by 108
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy
Jiang, L., Wang, Y., Zhao, J., Uehara, M., Hou, Q., Kasinath, V., Ichimura, T., Banouni, N., Dai, L., Li, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.045 · Cited by 117
“Although the generation of selective ligands with high binding affinity defines the current paradigm, many low-affinity drugs could also be effective (Csermely et al., 2005; Lipton, 2006; Mestres and Gregori-Puigjané, 2009).”
BackgroundBabiloni, C., Percio, C. D., Bordet, R., Bourriez, J., Bentivoglio, M., Payoux, P., Derambure, P., Dix, S. L., Infarinato, F., Lizio, R., et al. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.09.017 · Cited by 103
Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss
Birnbaum, J. H., Bali, J., Rajendran, L., Nitsch, R. M., & Tackenberg, C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.160 · Cited by 98
“Memantine, at clinically relevant low μM concentrations, is a low-affinity, uncompetitive open-channel blocker with a relatively high off-rate.(38) High-affinity NMDAR antagonists may be toxic after long exposure due to block of synaptic transmission.”
BackgroundUncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects
Li, S.-X., Han, Y., Xu, L.-Z., Yuan, K., Zhang, R.-X., Sun, C.-Y., Xu, D.-F., Yuan, M., Deng, J.-H., Meng, S.-Q., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.85 · Cited by 98
Pomara, C., Neri, M., Bello, S., Fiore, C., Riezzo, I., & Turillazzi, E. (2014) · Current Neuropharmacology · doi:10.2174/1570159x13666141210221434 · Cited by 111
“The term “excitotoxicity” was coined by John Olney [138, 139] to describe a specific neuronal death pathway induced by an excessive stimulation of glutamate receptors, resulting in excessive Ca influx through a receptor’s associated ion channels [140-142].”
BackgroundZindo, F. T., Joubert, J., & Malan, S. F. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.12 · Cited by 109
“By virtue of theoretical studies using 3D-QSAR models, they noted the amine feature as imperative for activity as similar amides showed no activity [64]. The same was true for ChE inhibitory activity, as the amide derivatives had a less potent activity profile. Bautista-Aguilera et al. (2014b) expanded on their series…”
BackgroundRosini, M., Simoni, E., Minarini, A., & Melchiorre, C. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1250-1 · Cited by 101
Kodis, E. J., Choi, S., Swanson, E., Ferreira, G., & Bloom, G. S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.05.017 · Cited by 89
“Interestingly, one of the few United States Food and Drug Administration–approved treatments for AD is memantine, which works by blocking excess calcium entry into neurons via NMDAR [26].”
BackgroundCognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 107
“synthesized at Lilly and patented in 1968 [779].”
One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
Hughes, R. E., Nikolic, K., & Ramsay, R. R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00177 · Cited by 93
“Memantine is the only approved NMDA receptor antagonist for the treatment of moderate to severe AD (Lipton, 2006).”
BackgroundElectrophilic warheads in covalent drug discovery: an overview
Péczka, N., Orgován, Z., Ábrányi‐Balogh, P., & Keserű, G. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2034783 · Cited by 93
NMDA Receptors, Glial Cells, and Clinical Medicine
Lipton, S. A. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.026 · Cited by 93
“This mode of drug action has been termed ‘‘Pathologically-Activated Therapeutics’’ or PAT drugs, that is, a gentle tap compared to most high-affinity drugs that manifest severe side effects, as previously produced by Big Pharma (Lipton, 2006).”
BackgroundSelf-citationDesigning transient binding drugs: A new concept for drug discovery
Ohlson, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.001 · Cited by 93
Neurologic Damage and Neurocognitive Dysfunction in Urea Cycle Disorders
Enns, G. M. (2008) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2008.05.007 · Cited by 93
Polycyclic Cage Structures as Lipophilic Scaffolds for Neuroactive Drugs
Joubert, J., Geldenhuys, W. J., der Schyf, C. J. V., Oliver, D. W., Kruger, H. G., Govender, T., & Malan, S. F. (2012) · ChemMedChem · doi:10.1002/cmdc.201100559 · Cited by 92
NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons
Gupta, K., Hardingham, G. E., & Chandran, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.03.010 · Cited by 85
“A major cause of glutamate excitotoxicity is activation of the NMDA subtype of glutamate receptor (NMDAR), which mediates Ca2+dependent cell death [26].”
Ceccom, J., Coslédan, F., Halley, H., Francès, B., Lassalle, J. M., & Meunier, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043105 · Cited by 88
“In order to validate this non-transgenic mouse model, we decided to compare the chelator PA1637 with clioquinol and memantine (MEM), a drug currently used for the treatment of severe Alzheimer’s disease [35,36].”
Nakamura, T., & Lipton, S. A. (2010) · Cell Calcium · doi:10.1016/j.ceca.2009.12.009 · Cited by 92
Self-citationGarzón, J., Rodríguez-Muñoz, M., & Sánchez‐Blázquez, P. (2012) · Current Drug Abuse Reviews · doi:10.2174/1874473711205030199 · Cited by 92
“disorders, including neurodegenerative diseases [35], mood disorders like schizophrenia and depression [36, 37], and neuropathic pain [38, 39].”
BackgroundGhatak, S., Talantova, M. V., McKercher, S. R., & Lipton, S. A. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032320-015420 · Cited by 95
Self-citationCosta, V. V., Sarto, J. L. D., Rocha, R. D. P. F., da Silva, F. R., Doria, J. G., Olmo, I. G., Marques, R. E., Queiroz‐Junior, C. M., Foureaux, G., Araújo, J. M. S., et al. (2017) · mBio · doi:10.1128/mbio.00350-17 · Cited by 98
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Merlos, M., & Garzón-Niño, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10095 · Cited by 92
“Of these, the NMDARs have received much attention because their deregulation is observed in many neurological disorders, such as neurodegenerative diseases [12], neuropathic pain [13, 14], mood disorders and psychosisschizophrenia [15, 16].”
BackgroundChotibut, T., Davis, R. W., Arnold, J. C., Frenchek, Z., Gurwara, S., Bondada, V., Geddes, J. W., & Salvatore, M. F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8598-0 · Cited by 86
“Unfortunately, however, the use of glutamate receptor antagonists in the Parkinson's disease patient have had mixed clinical outcomes [31–33] with some NMDAR antagonists, although showing promise in its ability to block excitotoxicity, can also inhibit normal excitatory synaptic activity leading to untoward side effec…”
The β isotypes of tubulin in neuronal differentiation
Guo, J., Walss‐Bass, C., & Ludueña, R. F. (2010) · Cytoskeleton · doi:10.1002/cm.20455 · Cited by 78
“…Glutamate/Glycine Glutamate is a neurotransmitter that, together with glycine, interacts with the N-methyl D-aspartate (NMDA) receptor in neurons; a side effect of this interaction is production of free radicals and ROS, including nitric oxide, superoxide anion, and peroxynitrite [Lipton, 2006].”
BackgroundMaekawa, M., Namba, T., Suzuki, E., Yuasa, S., Kohsaka, S., & Uchino, S. (2009) · Neuroscience Research · doi:10.1016/j.neures.2008.12.006 · Cited by 96
“Memantine is an uncompetitive NMDA receptor antagonist that has been used clinically as a neuroprotective agent to treat moderate-to-severe AD, but its use has not been associated with any of the adverse effects, such as the psychotomimetic and cardiovascular adverse effects, seen with other NMDA receptor antagonists…”
BackgroundThe calcium–iron connection in ferroptosis-mediated neuronal death
Gleitze, S., Paula-Lima, A. C., Núñez, M. T., & Hidalgo, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.231 · Cited by 91
Calcium Signaling and Neurodegeneration
Борисович, Б. И. (2010) · Acta Naturae · doi:10.32607/20758251-2010-2-1-72-80 · Cited by 97
“There is the possibility of developing even more specific inhibitors for the NMDA-receptor, such as nitromemantins [69].”
BackgroundDistribution and Dynamics of Adamantanes in a Lipid Bilayer
Chew, C. F., Guy, A. T., & Biggin, P. C. (2008) · Biophysical Journal · doi:10.1529/biophysj.108.139477 · Cited by 92
NMDA Receptors in Glial Cells: Pending Questions
Dzamba, D., Honsa, P., & Anderova, M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030002 · Cited by 81
The emergence of designed multiple ligands for neurodegenerative disorders
Geldenhuys, W. J., Youdim, M. B. H., Carroll, R. T., & der Schyf, C. J. V. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.010 · Cited by 96
White matter NMDA receptors: an unexpected new therapeutic target?
Stys, P. K., & Lipton, S. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.003 · Cited by 90
Self-citationCai, W., Li, L., Sang, S., Pan, X., & Zhong, C. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-022-00985-9 · Cited by 83
“Therefore, as a non-competitive, specific, low-affinity NMDAR antagonist with a fast closing rate, memantine is used to treat moderate to severe AD [206] since it can reduce excitotoxicity while preserving normal NMDAR activity at the same time.”
BackgroundGilling, K. E., Jatzke, C., Hechenberger, M., & Parsons, C. G. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.012 · Cited by 82
“It has further been suggested that the equilibrium blockade of NMDA receptor channels is dependent upon the concentration of agonist (Lipton, 2006).”
Oligodendrocyte NMDA receptors: a novel therapeutic target
Matute, C. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.05.004 · Cited by 84
Sánchez‐Blázquez, P., Rodríguez-Muñoz, M., Vicente‐Sánchez, A., & Garzón, J. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5100 · Cited by 85
“Multiple diseases, including stroke, head trauma, epilepsy, dementia, schizophrenia, major depression, Parkinson’s and Huntington’s diseases, and neuropathic pain, are accompanied by disturbances of N-methyl-D-aspartate receptor (NMDAR) signaling (39, 43, 49, 54).”
BackgroundXu, B., Li, X., He, G., Hu, J., Mu, X. L., Tian, S., & Du, G. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.038 · Cited by 81
“…includes treatment with acetylcholinesterase (AChE) inhibitors to improve cognitive function (Lleo et al., 2006), and a N-methyl-D-aspartate (NMDA) receptor antagonist, memantine (Lipton, 2006), has recently been approved for the treatment of advanced Alzheimer's disease in the United States.”
Molecular pharmacology of human NMDA receptors
Hedegaard, M. K., Hansen, K. B., Andersen, K. T., Bräuner‐Osborne, H., & Traynelis, S. F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.11.016 · Cited by 90
“The most recent NMDA receptor ligand to be approved for human use is the low-affinity channel blocker memantine (Alzheimer's disease) (Lipton, 2006).”
BackgroundNeuropeptidergic Mediators of Spontaneous Physical Activity and Non-Exercise Activity Thermogenesis
Teske, J. A., Billington, C. J., & Kotz, C. M. (2008) · Neuroendocrinology · doi:10.1159/000110802 · Cited by 79
NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models
Ghatak, S., Dolatabadi, N., Gao, R., Wu, Y., Scott, H., Trudler, D., Sultan, A., Ambasudhan, R., Nakamura, T., Masliah, E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0776-7 · Cited by 77
Self-citationNMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Vanle, B., Olcott, W., Jimenez, J., Bashmi, L., Danovitch, I., & IsHak, W. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0162-2 · Cited by 73
Multitarget Strategies in Alzheimer’S Disease: Benefits and Challenges on the Road to Therapeutics
Rosini, M., Simoni, E., Caporaso, R., & Minarini, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0003 · Cited by 88
Are we studying and treating schizophrenia correctly?
Swerdlow, N. R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.004 · Cited by 76
“…circuitry that could be recruited to enhance the effectiveness of CT. Memantine is neuroprotective (Kornhuber et al., 1994; Rogawski and Wenk, 2003; Lipton, 2006), enhances cortical metabolic efficiency (Willenborg et al., 2011), is well-tolerated by schizophrenia patients (Krivoy et al., 2008;…”
Sawant, N. A., Morton, H., Kshirsagar, S., Reddy, A. P., & Reddy, P. H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02556-x · Cited by 83
Memantine: Updating a rare success story in pro-cognitive therapeutics
Tari, P. K., Parsons, C. G., Collingridge, G. L., & Rammes, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109737 · Cited by 86
“…the pharmacological mechanism of action of memantine to be a strong voltage-dependent but low potency NMDAR un-competitive antagonism at clinically relevant concentrations (see reviews: Parsons et al., 1999; Danysz and Parsons, 2012; Lipton, 2006; Parsons et al., 2007; Rammes et al., 2008).”
BackgroundCalcium signalling: A common target in neurological disorders and neurogenesis
Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.12.002 · Cited by 79
Anti-dementia drugs and hippocampal-dependent memory in rodents
Yuede, C. M., Dong, H., & Csernansky, J. G. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282da278d · Cited by 76
“Unauthorized reproduction of this article is prohibited. from the receptor and so avoids prolonged NMDA-receptor blockade, which can be detrimental to learning and memory (Lipton, 2006).”
BackgroundSynapses, NMDA receptor activity and neuronal Aβ production in Alzheimer’s disease
Bordji, K., Becerril-Ortega, J., & Buisson, A. (2011) · revneuro · doi:10.1515/rns.2011.029 · Cited by 72
“To date, it is the only clinically AUTHOR’S COPY | AUTORENEXEMPLAR approved NMDAR antagonist for the treatment of moderateto-severe forms of AD (2002 in Europe; 2003 in the USA) (Chen and Lipton , 2006 ; Parsons et al. , 2007 ).”
BackgroundTalukder, I., Borker, P., & Wollmuth, L. P. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5382-09.2010 · Cited by 80
“As such, these linkers represent unexplored drug targets in which receptor activity can be regulated in a noncompetitive manner (Balannik et al., 2005), separate from the mostly failed approaches of competitive and allosteric modulators and pore blockers (Lipton, 2006; Kalia et al., 2008).”
BackgroundClassics in Chemical Neuroscience: Memantine
Alam, S., Lingenfelter, K. S., Bender, A. M., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00270 · Cited by 73
Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?
Caraci, F., Battaglia, G., Sortino, M. A., Spampinato, S. F., Molinaro, G., Copani, A., Nicoletti, F., & Bruno, V. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.01.017 · Cited by 83
Russo, R., Cavaliere, F., Rombolà, L., Gliozzi, M., Cerulli, A., Nucci, C., Fazzi, E. M., Bagetta, G., Corasaniti, M. T., & Morrone, L. A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)01139-4 · Cited by 74
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia
Light, G. A., Zhang, W., Joshi, Y. B., Bhakta, S. G., Talledo, J., & Swerdlow, N. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.81 · Cited by 78
“Memantine (MEM) is an uncompetitive NMDA receptor antagonist, with low affinity but rapid blocking and unblocking ability; its minimal impact on basal NMDA transmission distinguishes it mechanistically from other NMDA antagonists (Lipton, 2006).”
BackgroundFleming, T. M., Scott, V., Naskar, K., Joe, N., Brown, C. H., & Stern, J. E. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.207340 · Cited by 73
“…receptors To determine whether extrasynaptic NMDARs contribute to tonic INMDA in SON neurons, we tested the effects of memantine (MEM, 10–30 μM), an NMDAR antagonist that preferentially targets extrasynaptic receptors (Lipton, 2006; Leveille et al. 2008; Papadia et al. 2008; Okamoto et al. 2009).”
BackgroundKoeglsperger, T., Li, S., Brenneis, C., Saulnier, J. L., Mayo, L., Carrier, Y., Selkoe, D. J., & Weiner, H. L. (2013) · Glia · doi:10.1002/glia.22490 · Cited by 73
“Memantine is a low-affinity voltage-dependent antagonist at glutamatergic NMDARs (Rogawski and Wenk, 2003) that has been shown to preferentially block extrasynaptic NMDARs at low concentrations but preserves physiological synaptic transmission (Lipton, 2006; Xia et al., 2010).”
BackgroundAberrant Detergent-Insoluble Excitatory Amino Acid Transporter 2 Accumulates in Alzheimer Disease
Woltjer, R. L., Duerson, K., Fullmer, J. M., Mookherjee, P., Ryan, A. M., Montine, T. J., Kaye, J. A., Quinn, J. F., Silbert, L., Erten-Lyons, D., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e24adb · Cited by 72
“In this regard, memantine, a drug hypothesized to temper excessive NMDA receptor activation, has efficacy in treating AD (48).”
BackgroundFang, Y., Iu, C. Y. Y., Lui, C. N. P., Zou, Y., Fung, C. K. M., Li, H., Xi, N., Yung, K. K. L., & Lai, K. W. C. (2014) · Scientific Reports · doi:10.1038/srep07074 · Cited by 76
Hamilton, A., Zamponi, G. W., & Ferguson, S. S. G. (2015) · Molecular Brain · doi:10.1186/s13041-015-0107-0 · Cited by 78
“Of the drugs available for the treatment of AD, memantine, is a known allosteric blocker of NMDARs [93-96].”
BackgroundThe Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines
Swinney, D. C. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113501199 · Cited by 71
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.